+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free

Global Hypertrophic Cardiomyopathy Therapeutics Market to Witness Sluggish Growth; to Register 1.4% CAGR 2015-2023

Posted on Jul 01, 2016

The rising prevalence of chronic cardiovascular ailments has spurred the demand for effective therapeutics, thereby driving the global hypertrophic cardiomyopathy (HCM) therapeutics market. In a report titled “Hypertrophic Cardiomyopathy Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends, and Forecast, 2015 - 2023,” Transparency Market Research studies in detail the various factors fueling and challenging the global market. 

Browse the full Hypertrophic Cardiomyopathy Therapeutics Market: (By Drug Class: Beta Adrenergic Blocking Agents, Calcium Channel Blocker, Antiarrhythmic Agents, and Anticoagulants) - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends, and Forecast, 2015 - 2023 report at https://www.transparencymarketresearch.com/hypertrophic-cardiomyopathy-therapeutics-market.html

According to the American Heart Association, hypertrophic cardiomyopathy is a common condition that occurs when the muscle cells of the heart enlarge, causing the ventricle walls to thicken. HCM affects both men and women and is a common cause of sudden cardiac arrest in young people. The rising incidence of obstructive and non-obstructive hypertrophic cardiomyopathy is anticipated help the global market maintain a steady, albeit meager CAGR of 1.4% from 2015 to 2023. In 2014, the value of the hypertrophic cardiomyopathy therapeutics market was pegged at US$1.2 bn, which is forecast to increase to US$1.4 bn by 2023.

The global market for hypertrophic cardiomyopathy therapeutics has been studied on two fronts: By drug class and by geography.

Based on drug class, the hypertrophic cardiomyopathy therapeutics market has been categorized into calcium channel blockers, anticoagulants, beta adrenergic blocking agents, and antiarrhythmic agents. Although beta adrenergic blocking agents are the first preference for the treatment of obstructive as well as non-obstructive hypertrophic cardiomyopathy, calcium channel blockers form the largest segment in the overall market in terms of revenue. This can be attributed to the fact that the price of the latter blocking agents is much higher than that of the former.

By geography, the global hypertrophic cardiomyopathy therapeutics market comprises, Asia Pacific, North America, Europe, and Rest of the World. North America and Europe dominate the worldwide market, with the U.S. being the largest market for hypertrophic cardiomyopathy therapeutics. Accounting for a share of over 30% in 2014, the country is projected to retain is lead position throughout the forecast period. The hypertrophic cardiomyopathy therapeutics markets in Europe and North America are fueled by the rising prevalence of sedentary lifestyle among the younger population, the availability of modern healthcare infrastructure, and an increased presence of obesity. Growing awareness about hypertrophic cardiomyopathy and the various therapeutics available today has also significantly propelled the hypertrophic cardiomyopathy therapeutics market in these two regions.

Asia Pacific is predicted to be the fastest expanding market by 2023, fueled primarily by the rapid development in healthcare infrastructure, the increasing prevalence of various chronic diseases, and the growing awareness about various cardiac complications.

The report offers a detailed section on the competitive landscape of the global hypertrophic cardiomyopathy therapeutics market. The strengths, weaknesses, opportunities, and threats of each of the profiled players have also been examined in the report. Some of the promising companies in the hypertrophic cardiomyopathy therapeutics market are Teva Pharmaceuticals Limited, Gilead Sciences, Inc., Merck & Co., Inc., AstraZeneca plc, Concordia Healthcare Corp., Pfizer, Inc., Mylan N.V., Novartis AG, and Sanofi S.A.

Global Hypertrophic Cardiomyopathy Therapeutics, by Drug Class

  • Beta Adrenergic Blocking Agents
  • Calcium Channel Blockers
  • Antiarrhythmic Agents
  • Anticoagulants

Global Hypertrophic Cardiomyopathy Therapeutics, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia Pacific
    • India
    • Japan
    • Rest of Asia Pacific
  • Rest of the World
    • Latin America
    • Middle East
    • Africa

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.

Contact

Mr.Sudip S
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com

Back To Top